ARS Pharmaceuticals (SPRY) EBIT Margin (2022 - 2026)
ARS Pharmaceuticals' (SPRY) quarterly EBIT Margin came in at 265.18% in Q1 2026, up 20111.0% year-on-year from N/an in Q1 2025, and down 173.02% quarter-over-quarter from 363.14% in Q4 2025.
ARS Pharmaceuticals (SPRY) EBIT Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals has disclosed EBIT Margin across 5 years of filings, most recently posting 265.18% for Q1 2026.
- EBIT Margin for Q1 2026 came in at 265.18%, up 20111.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 59.56% (down 3169.0% YoY), and the FY2025 annual result was 42.7%, down 3924.0% from the prior year.
- EBIT Margin came in at 265.18% for Q1 2026 at ARS Pharmaceuticals, down from 363.14% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 363.14% in Q4 2025 to a low of 206030.0% in Q2 2023.
- The 5-year median for EBIT Margin is 1051.64% (2024), against an average of 23880.08%.
- Across the five-year window, EBIT Margin plunged 20466276 bps in 2023 and soared 20296200 bps in 2024, its largest moves.
- ARS Pharmaceuticals' EBIT Margin stood at 3507.94% in 2022, then slumped by 5773 bps to 206030.0% in 2023, then jumped by 100 bps to 54.51% in 2024, then surged by 566 bps to 363.14% in 2025, then sank by 173 bps to 265.18% in 2026.
- The last three EBIT Margin figures came in at 265.18% (Q1 2026), 363.14% (Q4 2025), and 163.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - | -265.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -265.18% |
| Dec 31, 2025 | 363.14% |
| Sep 30, 2025 | -163.66% |
| Jun 30, 2025 | -302.95% |
| Mar 31, 2025 | -466.29% |
| Dec 31, 2024 | 54.51% |
| Sep 30, 2024 | -1,051.64% |
| Jun 30, 2024 | -3,068.00% |
| Jun 30, 2023 | -206,030.00% |
| Mar 31, 2023 | -93,565.00% |
| Sep 30, 2022 | -3,507.94% |
| Jun 30, 2022 | -1,367.24% |
| Mar 31, 2022 | -1,070.74% |